Human Coagulation Factor VIII Market

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P?), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.
Human Coagulation Factor VIII Market contains market size and forecasts of Human Coagulation Factor VIII in global, including the following market information:
Global Human Coagulation Factor VIII Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Human Coagulation Factor VIII Market Sales, 2017-2022, 2023-2028, (K Bottles)
Global top five Human Coagulation Factor VIII companies in 2021 (%)
The global Human Coagulation Factor VIII market was valued at 10530 million in 2021 and is projected to reach US$ 15860 million by 2028, at a CAGR of 6.0% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Recombinant Factor VIII Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Human Coagulation Factor VIII include Shire (Baxter), Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk and Greencross, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Human Coagulation Factor VIII manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Coagulation Factor VIII Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Bottles)
Global Human Coagulation Factor VIII Market Segment Percentages, by Type, 2021 (%)
Recombinant Factor VIII
Plasma-derived Factor VIII
Global Human Coagulation Factor VIII Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Bottles)
Global Human Coagulation Factor VIII Market Segment Percentages, by Application, 2021 (%)
Hemophilia A
Spontanous / Trauma
Surgical
Other
Global Human Coagulation Factor VIII Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Bottles)
Global Human Coagulation Factor VIII Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Coagulation Factor VIII revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Human Coagulation Factor VIII revenues share in global market, 2021 (%)
Key companies Human Coagulation Factor VIII sales in global market, 2017-2022 (Estimated), (K Bottles)
Key companies Human Coagulation Factor VIII sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS